Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Common Equity (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Common Equity for 8 consecutive years, with $136.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 159.75% to $136.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136.3 million through Dec 2025, up 159.75% year-over-year, with the annual reading at $136.3 million for FY2025, 159.75% up from the prior year.
  • Common Equity for Q4 2025 was $136.3 million at Whitehawk Therapeutics, down from $157.2 million in the prior quarter.
  • The five-year high for Common Equity was $221.7 million in Q1 2025, with the low at -$19.4 million in Q2 2021.
  • Average Common Equity over 5 years is $114.5 million, with a median of $128.0 million recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 836.54% in 2021, then crashed 50.11% in 2024.
  • Over 5 years, Common Equity stood at $136.4 million in 2021, then grew by 16.11% to $158.4 million in 2022, then plummeted by 33.58% to $105.2 million in 2023, then plummeted by 50.11% to $52.5 million in 2024, then surged by 159.75% to $136.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $136.3 million, $157.2 million, and $172.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.